Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2027-07-27
Target enrollment:
Participant gender:
Summary
This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b)
study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy
with the combination of tipifarnib with osimertinib in patients with advanced/metastatic
EGFR-mutated non-small cell lung cancer.